These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 31253727

  • 1. NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.
    Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.
    J Immunol; 2019 Aug 01; 203(3):705-717. PubMed ID: 31253727
    [Abstract] [Full Text] [Related]

  • 2. Pegylated Interferon-α-Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients.
    Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, Garcia-Broncano P, Marchetti G, Genebat M, Leal M, Resino S, Ruiz-Mateos E, Lichterfeld M, Yu XG.
    Clin Infect Dis; 2018 Jun 01; 66(12):1910-1917. PubMed ID: 29272392
    [Abstract] [Full Text] [Related]

  • 3. Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment.
    Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, Autran B, Clotet B, Blanco J.
    Antivir Ther; 2010 Jun 01; 15(3):333-42. PubMed ID: 20516553
    [Abstract] [Full Text] [Related]

  • 4. Safety, Immune, and Antiviral Effects of Pegylated Interferon Alpha 2b Administration in Antiretroviral Therapy-Suppressed Individuals: Results of Pilot Clinical Trial.
    Papasavvas E, Azzoni L, Pagliuzza A, Abdel-Mohsen M, Ross BN, Fair M, Howell BJ, Hazuda DJ, Chomont N, Li Q, Mounzer K, Kostman JR, Tebas P, Montaner LJ.
    AIDS Res Hum Retroviruses; 2021 Jun 01; 37(6):433-443. PubMed ID: 33323024
    [Abstract] [Full Text] [Related]

  • 5. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J, González-García J, López-Aldeguer J, Von-Wichmann MA, Quereda C, Hernando A, Sanz J, Tural C, Ortega E, Mallolas J, Santos I, Miralles P, Montes ML, Bellón JM, Esteban H, GESIDA HIV/HCV cohort.
    J Antimicrob Chemother; 2009 Jun 01; 63(6):1256-63. PubMed ID: 19363085
    [Abstract] [Full Text] [Related]

  • 6. Short-Term Pegylated Interferon α2a Treatment Does Not Significantly Reduce the Viral Reservoir of Simian Immunodeficiency Virus-Infected, Antiretroviral Therapy-Treated Rhesus Macaques.
    Palesch D, Bosinger SE, Mavigner M, Billingsley JM, Mattingly C, Carnathan DG, Paiardini M, Chahroudi A, Vanderford TH, Silvestri G.
    J Virol; 2018 Jul 15; 92(14):. PubMed ID: 29720521
    [Abstract] [Full Text] [Related]

  • 7. Upregulation of NKG2C+ natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB.
    Yan W, Wu D, Wang X, Chen T, Lai Q, Zheng Q, Jiang J, Hou J, Han M, Ning Q.
    Antivir Ther; 2015 Jul 15; 20(6):591-602. PubMed ID: 25814467
    [Abstract] [Full Text] [Related]

  • 8. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E, Barreiro P, Rodriguez-Nóvoa S, Morello J, Labarga P, Martín-Carbonero L, Maida I, García-Gascó P, Soriano V.
    Antivir Ther; 2008 Jul 15; 13(4):511-7. PubMed ID: 18672529
    [Abstract] [Full Text] [Related]

  • 9. Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity.
    Azzoni L, Papasavvas E, Chehimi J, Kostman JR, Mounzer K, Ondercin J, Perussia B, Montaner LJ.
    J Immunol; 2002 Jun 01; 168(11):5764-70. PubMed ID: 12023377
    [Abstract] [Full Text] [Related]

  • 10. Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion.
    Bruder Costa J, Dufeu-Duchesne T, Leroy V, Bertucci I, Bouvier-Alias M, Pouget N, Brevot-Lutton O, Bourliere M, Zoulim F, Plumas J, Aspord C, ANRS HB06 PEGAN study group.
    PLoS One; 2016 Jun 01; 11(6):e0158297. PubMed ID: 27348813
    [Abstract] [Full Text] [Related]

  • 11. Comparable HIV suppression by pegylated-IFN-α2a or pegylated-IFN-α2b during a 4-week analytical treatment interruption.
    Papasavvas E, Azzoni L, Ross BN, Fair M, Howell BJ, Hazuda DJ, Mounzer K, Kostman JR, Tebas P, Montaner LJ.
    AIDS; 2021 Oct 01; 35(12):2051-2054. PubMed ID: 34049356
    [Abstract] [Full Text] [Related]

  • 12. HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.
    Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.
    J Viral Hepat; 2017 Oct 01; 24(10):865-876. PubMed ID: 28419653
    [Abstract] [Full Text] [Related]

  • 13. Contribution of NK cells to HBsAg seroconversion in inactive HBsAg carriers following pegylated IFN therapy.
    Cao Z, Meng S, Zheng Y, Wang J, Wang R, Chen X.
    Innate Immun; 2020 Oct 01; 26(7):601-608. PubMed ID: 32772775
    [Abstract] [Full Text] [Related]

  • 14. The Education of NK Cells Determines Their Responsiveness to Autologous HIV-Infected CD4 T Cells.
    Kiani Z, Dupuy FP, Bruneau J, Lebouché B, Retière C, Geraghty DE, Bernard NF.
    J Virol; 2019 Dec 01; 93(23):. PubMed ID: 31511383
    [Abstract] [Full Text] [Related]

  • 15. A multiphase model of the dynamics of HBV infection in HBeAg-negative patients during pegylated interferon-alpha2a, lamivudine and combination therapy.
    Colombatto P, Civitano L, Bizzarri R, Oliveri F, Choudhury S, Gieschke R, Bonino F, Brunetto MR, Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group.
    Antivir Ther; 2006 Dec 01; 11(2):197-212. PubMed ID: 16640101
    [Abstract] [Full Text] [Related]

  • 16. IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation.
    Tomescu C, Tebas P, Montaner LJ.
    AIDS; 2017 Mar 13; 31(5):613-622. PubMed ID: 28225449
    [Abstract] [Full Text] [Related]

  • 17. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
    Offersen R, Nissen SK, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.
    J Virol; 2016 May 13; 90(9):4441-4453. PubMed ID: 26889036
    [Abstract] [Full Text] [Related]

  • 18. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.
    Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, Kramski M, Hearps AC, Cameron PU, Lewin SR, Crowe SM, Jaworowski A.
    J Immunol; 2012 Aug 01; 189(3):1491-9. PubMed ID: 22745371
    [Abstract] [Full Text] [Related]

  • 19. Interferon-alpha restores HIV-induced alteration of natural killer cell perforin expression in vivo.
    Portales P, Reynes J, Pinet V, Rouzier-Panis R, Baillat V, Clot J, Corbeau P.
    AIDS; 2003 Mar 07; 17(4):495-504. PubMed ID: 12598769
    [Abstract] [Full Text] [Related]

  • 20. Increased Natural Killer Cell Activation in HIV-Infected Immunologic Non-Responders Correlates with CD4+ T Cell Recovery after Antiretroviral Therapy and Viral Suppression.
    Luo Z, Li Z, Martin L, Hu Z, Wu H, Wan Z, Kilby M, Heath SL, Huang L, Jiang W.
    PLoS One; 2017 Mar 07; 12(1):e0167640. PubMed ID: 28076376
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.